Yu 2007.

Methods	Study design: RCT Time frame: NR Follow‐up period: 8 weeks
Participants	Country: South Korea Setting: NR Inclusion criteria: HD or PD therapy and TC > 170 mg/dL Number (treatment 1/treatment 2): NR Age: NR Sex (M/F): NR Exclusion criteria: NR
Interventions	Treatment group 1 Simvastatin Dose: 10 mg/d Ezetimibe Dose: 10 mg/d Treatment duration: 8 weeks Treatment group 2 Ezetimibe Dose: 10 mg/d Treatment duration: 8 weeks
Outcomes	CRP TC, LDL Fibrinogen, Von Willebrand factor, D‐dimer
Notes	Abstract publication only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NR
Allocation concealment (selection bias)	Unclear risk	NR
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	NR
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear
Selective reporting (reporting bias)	High risk	Publication reports did not provide all expected outcomes
ITT analysis	Unclear risk	NR

ALT ‐ alanine aminotransferase; APD ‐ automated peritoneal dialysis; Apo ‐ apoprotein; AST ‐ aspartate aminotransferase; AMI ‐ acute myocardial infarction; BP ‐ blood pressure; CABG ‐ coronary artery bypass graft; CAPD ‐ continuous ambulatory peritoneal dialysis; CHF ‐ chronic heart failure; CK ‐ creatine kinase; CKD ‐ chronic kidney disease; CRP ‐ C‐reactive protein; CVA ‐ cerebrovascular accident; CVD ‐ cardiovascular disease; DM ‐ diabetes mellitus; ESKD ‐ end‐stage kidney disease; ESR ‐ erythrocyte sedimentation rate; HD ‐ haemodialysis; HDL ‐ high‐density lipoprotein; HRT ‐ hormone replacement therapy; hs‐CRP ‐ highly‐sensitive CRP; IL‐6 ‐ interleukin 6; ITT ‐ intention‐to‐treat; LDL ‐ low‐density lipoprotein; LFT ‐ liver function test; MI ‐ myocardial infarction; NR ‐ not reported; NSAIDs ‐ non‐steroidal anti‐inflammatory drugs; PD ‐ peritoneal dialysis; PTCA ‐ percutaneous transluminal coronary angioplasty; SCr ‐ serum creatinine; TC ‐ total cholesterol; TG ‐ triglycerides; ULN ‐ upper limit of normal